Protocol Ledger

NCT05283226 · Phase II · RECRUITING

Study to Evaluate the Safety and Efficacy of Oral NRC-2694-A in Combination With Paclitaxel in Patients With Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma, Who Progressed on or After Immune Checkpoint

Interventional Phase II clinical trial protocol NCT05283226 sponsored by NATCO Pharma in Oncology and Hematology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2022-09-30 Enrollment: 21 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT05283226
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)21 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT05283226
Protocol FieldVerified Registry Value
NCT IdentifierNCT05283226
Consolidated Lead SponsorNATCO Pharma
Therapeutic Condition CohortOncology and Hematology
Clinical Trial PhasePhase II
Overall Recruitment StatusRECRUITING
Registered Enrollment21 participants (ESTIMATED)
Registered Start Date2022-09-30
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Search related sites and sponsors in the Interactive Directory, explore Oncology and Hematology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI